|By PR Newswire||
|April 21, 2014 04:00 PM EDT||
LOS ANGELES, April 21, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the abstract describing the Company's phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 American Society for Clinical Oncology (ASCO) annual meeting, to be held in Chicago May 30-June 3, 2014.
The abstract accepted for oral presentation is titled, "A randomized, double‑blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients." The principal investigator on the study, Patrick Y. Wen, MD, Director, Center for Neuro-Oncology, Dana Farber Cancer Institute, and Professor Neurology, Harvard Medical School, will present during the session titled, Central Nervous System Tumors, on Sunday, June 1st at 8:00-11:00 am CT. Dr. Wen's presentation is scheduled for 10:00-10:12 am CT. The abstract number is 2005.
"We are honored that the ASCO Scientific Program Committee has selected our work in newly diagnosed GBM for oral presentation, typically reserved for important clinical and translational research findings," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We are looking forward to discussing the ICT-107 phase II results with key opinion leaders in the neuro-oncology community during, and in conjunction with, our presentation. We anticipate presenting updated overall survival results for both the whole trial population and key predefined sub-groups, as well as important immunological analyses that can provide insights relative to vaccine potency and response. This larger and richer data set will be the basis for informing our phase III design and execution strategies. We look forward to Dr. Wen's presentation, and want to express our sincere appreciation for the ongoing interest and support within the neuro-oncology community for ICT-107's continued development."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
SOURCE ImmunoCellular Therapeutics, Ltd.
Sep. 27, 2016 09:30 AM EDT Reads: 2,649
Sep. 27, 2016 09:15 AM EDT Reads: 2,292
Sep. 27, 2016 09:00 AM EDT Reads: 2,655
Sep. 27, 2016 08:45 AM EDT Reads: 2,574
Sep. 27, 2016 08:30 AM EDT Reads: 2,638
Sep. 27, 2016 08:15 AM EDT Reads: 2,625
"We have several customers now running private clouds. They're not as large as they should be but it's getting there. The adoption challenge has been pretty simple. Look at the world today of virtualization vs cloud," stated Nara Rajagopalan, CEO of Accelerite, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Sep. 27, 2016 08:00 AM EDT Reads: 2,230
Sep. 27, 2016 08:00 AM EDT Reads: 3,698
Sep. 27, 2016 08:00 AM EDT Reads: 2,783
Sep. 27, 2016 08:00 AM EDT Reads: 1,993
Sep. 27, 2016 08:00 AM EDT Reads: 1,094
Sep. 27, 2016 08:00 AM EDT Reads: 2,516
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm ...
Sep. 27, 2016 07:45 AM EDT Reads: 3,287
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
Sep. 27, 2016 07:45 AM EDT Reads: 2,499
From wearable activity trackers to fantasy e-sports, data and technology are transforming the way athletes train for the game and fans engage with their teams. In his session at @ThingsExpo, will present key data findings from leading sports organizations San Francisco 49ers, Orlando Magic NBA team. By utilizing data analytics these sports orgs have recognized new revenue streams, doubled its fan base and streamlined costs at its stadiums. John Paul is the CEO and Founder of VenueNext. Prior ...
Sep. 27, 2016 07:30 AM EDT Reads: 2,976